Novo Nordisk Slashes Long-Term Profit Growth on Pricing

The transcript discusses the challenges faced by pharmaceutical companies, particularly in the insulin market, due to pricing pressures and competition from biosimilars. It highlights the contrasting trends between pharma and banking stocks, influenced by regulatory concerns and market dynamics. The financial position of Novo is analyzed, noting its high margins but potential future challenges.

Discuss the challenges faced by Novo in maintaining their profit margins.

What does the speaker mean by 'we're just at the beginning of the storm' in relation to the pharmaceutical market?